RBF Capital’s ImmuCell ICCC Stock Holding History

RBF Capital’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,086	Closed	-$78K	–	452
2020 Q4	$78K	Hold	13,086	–	–	0.01%	386
2020 Q3	$71K	Hold	13,086	–	–	0.01%	360
2020 Q2	$62K	Buy	+13,086	New	+$57K	0.01%	378
2020 Q1	–	Sell	-13,086	Closed	-$66K	–	383
2019 Q4	$66K	Hold	13,086	–	–	0.01%	376
2019 Q3	$73K	Hold	13,086	–	–	0.01%	370
2019 Q2	$85K	Hold	13,086	–	–	0.01%	374
2019 Q1	$83K	Hold	13,086	–	–	0.01%	363
2018 Q4	$92K	Hold	13,086	–	–	0.01%	365
2018 Q3	$109K	Hold	13,086	–	–	0.01%	375
2018 Q2	$90K	Hold	13,086	–	–	0.01%	365
2018 Q1	$92K	Hold	13,086	–	–	0.01%	353
2017 Q4	$115K	Buy	+13,086	New	+$107K	0.01%	343

Other funds holding ICCC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMC

Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

RBF Capital's ICCC Position: Q1 2021 in Review

RBF Capital sold out of ImmuCell (ICCC) in Q1 2021, closing a stake of 13,086 shares — an estimated $78K sold.

RBF Capital first reported a position in ICCC in Q4 2017 and held it in 12 quarters. The position peaked at $115K in Q4 2017. 28 funds tracked by Wall St. Rank hold ICCC as of Q1 2021.

RBF Capital reported no remaining ImmuCell position as of Q1 2021 after selling out during the quarter.
RBF Capital sold 13,086 ImmuCell shares in Q1 2021, an estimated $78K.
RBF Capital first reported a position in ImmuCell in Q4 2017 and held it in 12 quarters.
RBF Capital's ImmuCell position peaked at $115K in Q4 2017.
28 funds tracked by Wall St. Rank held ImmuCell as of Q1 2021.

Based on RBF Capital's 13F filing for Q1 2021, filed 17 May 2021.